share_log

JP Morgan Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $45

Benzinga ·  Dec 28, 2023 05:52

JP Morgan analyst Jessica Fye maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price target from $25 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment